Takeda Pharmaceutical (TAK) Common Equity (2017 - 2026)

Takeda Pharmaceutical has reported Common Equity for 10 years, with the latest figure at $47.4 billion in Q2 2026.

• On a quarterly basis, Common Equity changed 0.06% year-over-year to $47.4 billion in Q2 2026; TTM through Jun 2026 was $47.4 billion, a 0.06% change from a year earlier, with the FY2026 full-year figure at $47.4 billion, up 4.06% from the prior year.
• Common Equity was $47.4 billion for Q2 2026 at Takeda Pharmaceutical, roughly flat from $47.4 billion in the prior quarter.
• The five-year high for Common Equity was $50.5 billion in Q2 2023, with the low at $43.7 billion in Q4 2022.
• Average Common Equity over 5 years is $48.1 billion, with a median of $48.6 billion recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Common Equity grew 6.99% in 2024, then decreased 7.38% in 2025.
• Over 5 years, Common Equity stood at $43.7 billion in 2022, then grew by 4.34% to $45.6 billion in 2023, then advanced by 6.99% to $48.8 billion in 2024, then advanced by 1.78% to $49.7 billion in 2025, then fell by 4.52% to $47.4 billion in 2026.
• The last three Common Equity figures came in at $47.4 billion (Q2 2026), $47.4 billion (Q1 2026), and $49.7 billion (Q4 2025), per Business Quant data.